Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 6th Preview)
-
Big pharma dealmaking in immunology
UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, a deal designed to expand UCB’s portfolio of T-cell engager (TCE) antibodies in autoimmune and inflammatory disease. The transaction adds Candid’s lead BCMA/CD3 bispecific, cizutamig (CND-106), plus the company’s early pipeline of bispecific and trispecific candidates. Candid’s cizutamig is aimed at autoantibody-driven diseases by directing cytotoxicity toward plasma cells (via BCMA) and T cells (via CD3), with the goal of limiting cytokine release. It is already in multiple Phase 1 studies across more than 10 autoimmune indications and has completed multiple myeloma evaluation in over 40 patients. The agreement also follows Candid’s earlier plan to pursue a reverse merger with Rallybio, which would have kept the Candid name while creating new publicly traded shares. UCB’s bid effectively resets that path and underscores big pharma’s appetite for China-sourced autoimmune assets. The deal is expected to close in the second or third quarter of 2026, keeping pressure on translational teams to integrate early clinical manufacturing, safety data, and regulatory execution across geographies.
-
FDA real-time clinical trial pilots
The FDA is moving to speed up early drug development by piloting real-time clinical trials (RTCTs), where sponsors report endpoint and signal data to the agency as it is generated. The agency says it has validated the technical framework for real-time signal sharing, establishing feasibility through pilot activity with sponsors including AstraZeneca. The FDA’s approach focuses on reducing the lag between trial completion of key endpoints and FDA visibility into emerging safety signals. It also plans an RFI process to select additional pilot participants later this year, with input due by the end of May. If expanded, RTCTs could change how investigators design early-phase programs and how companies respond to safety signals during enrollment. The FDA also frames the effort as part of a broader modernization push aimed at faster initial human studies. For sponsors, the immediate impact will be on internal trial reporting workflows and agreements for real-time data exchange with regulators, potentially compressing timelines for go/no-go decisions.
-
Late-breaking clinical efficacy in cardiomyopathy
Cytokinetics said its Phase 3 ACACIA trial hit twin efficacy goals in symptomatic, non-obstructive hypertrophic cardiomyopathy, with Myqorzo (aficamten) improving both patient-reported symptom scores and cardiovascular fitness versus placebo. The results position the company to expand treatment eligibility beyond obstructive HCM, where the drug already has regulatory traction. The company reported statistically significant improvements from baseline to Week 36 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and maximal exercise performance, using an allosteric, reversible inhibitor of cardiac myosin motor activity. The outcome also builds on Cytokinetics’ earlier obstructive HCM approval. Analysts noted the competitive and commercial significance: an expanded indication could increase the addressable market while differentiating against Bristol Myers Squibb’s rival program, which had previously been separated by disease form. Regulatory review remains the next gate, but the clinical signal is strong enough to reshape near-term payer and clinical adoption expectations for Myqorzo across HCM subtypes.
-
Phase 3 regulatory track for chronic thyroid eye disease
Viridian Therapeutics posted positive Phase 3 top-line results for elegrobart (VRDN-003) in chronic thyroid eye disease, clearing the way for planned regulatory filings. The company said the trial met both primary endpoints needed for a U.S. BLA and an EMA submission. Elegrobart, delivered subcutaneously via autoinjector for at-home use, targets the insulin-like growth factor-1 receptor with a half-life extension. The endpoints included a proptosis responder rate measured by exophthalmometry for the U.S. filing and an overall responder rate for the European pathway. The update intensifies competition in TED, a progressive autoimmune condition, by adding a next-generation candidate alongside Amgen’s Tepezza and Viridian’s own veligrotug in FDA review. Market attention is likely to focus on durability, safety tolerability, and responder definitions as companies prepare for regulator-facing packages. With the filing window anticipated for early 2027, the Phase 3 readout also changes how clinicians may sequence TED therapy lines in Graves’ eye disease.
-
Drug discovery platform: AI-enabled diagnostic growth and partnerships
Tempus reported a 36% year-over-year increase in Q1 revenue to $348.1 million and raised full-year guidance, citing acceleration in oncology testing and continued demand for its AI-enabled diagnostic platform. The company also reported a sixfold jump in minimal residual disease (MRD) testing volume to about 6,500 tests, along with hereditary testing growth. Tempus said R&D spending increased 34% year over year to $48.2 million and described operational momentum across its multimodal Lens platform. It also announced a multi-year collaboration with Merck for biomarker discovery and development using Tempus data and Lens analytics. In parallel, Tempus expanded an enterprise collaboration with Gilead to provide access to the Lens platform and datasets for oncology pipeline development. The company exited the quarter with $521.2 million in cash and cash equivalents. Investors are likely to track whether the raised guidance is sustained as MRD and hereditary testing volumes scale, and whether the Merck and Gilead agreements translate into additional model development and commercial utilization.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.